Stockreport

Bellicum Announces Favorable Interim Event-Free Survival Data for Rivo-cel Treated Patients in Presentation at ASH 2018

Bellicum Pharmaceuticals, Inc.  (BLCM) 
Last bellicum pharmaceuticals, inc. earnings: 3/12 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.bellicum.com/investor-overview
PDF Interim results suggest rivo-cel outcomes were comparable to a control study of transplants from matched unrelated donors, a requirement for product registration in Euro [Read more]